Literature DB >> 33436495

Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis.

Gabriel Mezzano1,2, Adria Juanola1,3,4, Andres Cardenas3,4,5, Esteban Mezey6, James P Hamilton6, Elisa Pose1,3,4, Isabel Graupera1,3,4,7, Pere Ginès1,3,4,7, Elsa Solà1,3,4,7, Ruben Hernaez8,9,10.   

Abstract

BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is characterised by acute decompensation of cirrhosis associated with organ failures. We systematically evaluated the geographical variations of ACLF across the world in terms of prevalence, mortality, aetiology of chronic liver disease (CLD), triggers and organ failures.
METHODS: We searched EMBASE and PubMed from 3/1/2013 to 7/3/2020 using the ACLF-EASL-CLIF (European Association for the Study of the Liver-Chronic Liver Failure) criteria. Two investigators independently conducted the abstract selection/abstraction of the aetiology of CLD, triggers, organ failures and prevalence/mortality by presence/grade of ACLF. We grouped countries into Europe, East/South Asia and North/South America. We calculated the pooled proportions, evaluated the methodological quality using the Newcastle-Ottawa Scale and statistical heterogeneity, and performed sensitivity analyses.
RESULTS: We identified 2369 studies; 30 cohort studies met our inclusion criteria (43 206 patients with ACLF and 140 835 without ACLF). The global prevalence of ACLF among patients admitted with decompensated cirrhosis was 35% (95% CI 33% to 38%), highest in South Asia at 65%. The global 90-day mortality was 58% (95% CI 51% to 64%), highest in South America at 73%. Alcohol was the most frequently reported aetiology of underlying CLD (45%, 95% CI 41 to 50). Infection was the most frequent trigger (35%) and kidney dysfunction the most common organ failure (49%). Sensitivity analyses showed regional estimates grossly unchanged for high-quality studies. Type of design, country health index, underlying CLD and triggers explained the variation in estimates.
CONCLUSIONS: The global prevalence and mortality of ACLF are high. Region-specific variations could be explained by the type of triggers/aetiology of CLD or grade. Health systems will need to tailor early recognition and treatment of ACLF based on region-specific data. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cirrhosis; liver failure

Mesh:

Year:  2021        PMID: 33436495     DOI: 10.1136/gutjnl-2020-322161

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

Review 1.  Alcohol and Acute-on-Chronic Liver Failure.

Authors:  Maria Pilar Ballester; Richard Sittner; Rajiv Jalan
Journal:  J Clin Exp Hepatol       Date:  2021-12-22

Review 2.  Palliative Care in the Patient With Acute-on-Chronic Liver Failure.

Authors:  Kinjal Patel; Puneeta Tandon; Ruben Hernaez
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-05-20

3.  Risk Factors for Posttransplantation Mortality in Recipients With Grade 3 Acute-on-Chronic Liver Failure: Analysis of a North American Consortium.

Authors:  Vinay Sundaram; Sarvanand Patel; Kirti Shetty; Christina C Lindenmeyer; Robert S Rahimi; Gianina Flocco; Atef Al-Attar; Constantine J Karvellas; Suryanarayana Challa; Harapriya Maddur; Janice H Jou; Michael Kriss; Lance L Stein; Alex H Xiao; Ross H Vyhmeister; Ellen W Green; Braidie Campbell; William Cranford; Nadim Mahmud; Brett E Fortune
Journal:  Liver Transpl       Date:  2022-02-09       Impact factor: 6.112

4.  The impact of recipient age on the effects of umbilical cord mesenchymal stem cells on HBV-related acute-on-chronic liver failure and liver cirrhosis.

Authors:  Ka Zhang; Haixia Sun; Huijuan Cao; Yifan Jia; Xin Shu; Hong Cao; Yufeng Zhang; Xiaoan Yang
Journal:  Stem Cell Res Ther       Date:  2021-08-20       Impact factor: 6.832

5.  Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.

Authors:  Mark M Davis; Pere Ginès; Elisa Pose; Elsa Solà; Juan J Lozano; Adrià Juanola; Julia Sidorova; Giacomo Zaccherini; Koos de Wit; Frank Uschner; Marta Tonon; Konstantin Kazankov; Cesar Jiménez; Daniela Campion; Laura Napoleone; Ann T Ma; Marta Carol; Manuel Morales-Ruiz; Carlo Alessandria; Ulrich Beuers; Paolo Caraceni; Claire Francoz; François Durand; Rajeshwar P Mookerjee; Jonel Trebicka; Victor Vargas; Salvatore Piano; Hugh Watson; Juan G Abraldes; Patrick S Kamath
Journal:  Hepatol Commun       Date:  2021-12-28

6.  Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?

Authors:  Fabian Finkelmeier; Kai-Henrik Peiffer; Esra Görgülü; Wenyi Gu; Jonel Trebicka; Victoria Therese Mücke; Marcus Maximilian Muecke; Mireen Friedrich-Rust; Joerg Bojunga; Stefan Zeuzem
Journal:  Gut       Date:  2021-06-17       Impact factor: 23.059

7.  Acute on chronic liver failure in cirrhosis.

Authors:  Marta Tonon; Salvatore Piano
Journal:  Clin Mol Hepatol       Date:  2022-02-14

8.  Different Effects of Total Bilirubin on 90-Day Mortality in Hospitalized Patients With Cirrhosis and Advanced Fibrosis: A Quantitative Analysis.

Authors:  Liang Qiao; Wenting Tan; Xiaobo Wang; Xin Zheng; Yan Huang; Beiling Li; Zhongji Meng; Yanhang Gao; Zhiping Qian; Feng Liu; Xiaobo Lu; Jia Shang; Junping Liu; Huadong Yan; Wenyi Gu; Yan Zhang; Xiaomei Xiang; Yixin Hou; Qun Zhang; Yan Xiong; Congcong Zou; Jun Chen; Zebing Huang; Xiuhua Jiang; Sen Luo; Yuanyuan Chen; Na Gao; Chunyan Liu; Wei Yuan; Xue Mei; Jing Li; Tao Li; Rongjiong Zheng; Xinyi Zhou; Jinjun Chen; Guohong Deng; Weituo Zhang; Hai Li
Journal:  Front Med (Lausanne)       Date:  2021-06-23

9.  Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic.

Authors:  Thorben Fründt; Lilith Kuballa; Marc Lütgehetman; Dominik Nörz; Hannes Arend; Thomas T Brehm; Julian Schulze Zur Wiesch; Thomas Horvatits; Karoline Horvatits; Samuel Huber; Henning Wege; Johannes Kluwe
Journal:  PLoS One       Date:  2021-12-23       Impact factor: 3.240

10.  Acute-on-chronic liver failure: a global disease.

Authors:  Martin Schulz; Jonel Trebicka
Journal:  Gut       Date:  2021-02-25       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.